Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.1231 | 0.6997 | 0.5 |
Schistosoma mansoni | glutamate receptor NMDA | 0.0199 | 0.0209 | 0.0209 |
Echinococcus multilocularis | geminin | 0.0196 | 0.0191 | 0.0191 |
Echinococcus multilocularis | thymidylate synthase | 0.0468 | 0.1978 | 0.1978 |
Echinococcus granulosus | glutamate receptor 2 | 0.0199 | 0.0209 | 0.0209 |
Echinococcus multilocularis | dihydrofolate reductase | 0.1688 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0196 | 0.0191 | 0.0191 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 2 | 0.0199 | 0.0209 | 0.0209 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.022 | 0.035 | 0.035 |
Schistosoma mansoni | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0468 | 0.1978 | 0.1978 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0223 | 0.0364 | 0.5 |
Echinococcus multilocularis | glutamate receptor, ionotrophic, AMPA 3 | 0.0199 | 0.0209 | 0.0209 |
Echinococcus granulosus | geminin | 0.0196 | 0.0191 | 0.0191 |
Mycobacterium tuberculosis | Probable thymidylate synthase ThyA (ts) (TSASE) | 0.0468 | 0.1978 | 0.1674 |
Schistosoma mansoni | hypothetical protein | 0.0196 | 0.0191 | 0.0191 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.1231 | 0.6997 | 1 |
Echinococcus granulosus | Glutamate receptor ionotropic kainate 2 | 0.0199 | 0.0209 | 0.0209 |
Onchocerca volvulus | 0.0468 | 0.1978 | 0.5 | |
Schistosoma mansoni | dihydrofolate reductase | 0.1688 | 1 | 1 |
Echinococcus granulosus | glutamate receptor ionotrophic AMPA 3 | 0.0199 | 0.0209 | 0.0209 |
Echinococcus granulosus | thymidylate synthase | 0.0468 | 0.1978 | 0.1978 |
Brugia malayi | Dihydrofolate reductase | 0.1688 | 1 | 1 |
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.1688 | 1 | 1 |
Echinococcus granulosus | Glutamate receptor ionotropic kainate 2 | 0.0199 | 0.0209 | 0.0209 |
Brugia malayi | hypothetical protein | 0.0223 | 0.0364 | 0.0364 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 3 | 0.022 | 0.035 | 0.035 |
Loa Loa (eye worm) | dihydrofolate reductase | 0.1688 | 1 | 1 |
Brugia malayi | thymidylate synthase | 0.0468 | 0.1978 | 0.1978 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.1231 | 0.6997 | 0.5 |
Echinococcus granulosus | nmda type glutamate receptor | 0.022 | 0.035 | 0.035 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 2 | 0.0199 | 0.0209 | 0.0209 |
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.1688 | 1 | 1 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.1231 | 0.6997 | 0.5 |
Chlamydia trachomatis | dihydrofolate reductase | 0.1688 | 1 | 0.5 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.1231 | 0.6997 | 0.5 |
Echinococcus granulosus | dihydrofolate reductase | 0.1688 | 1 | 1 |
Echinococcus granulosus | Glutamate receptor ionotropic kainate 2 | 0.0199 | 0.0209 | 0.0209 |
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.1688 | 1 | 1 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 2 | 0.0199 | 0.0209 | 0.0209 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.1231 | 0.6997 | 0.5 |
Loa Loa (eye worm) | thymidylate synthase | 0.0468 | 0.1978 | 0.1978 |
Echinococcus multilocularis | glutamate receptor 2 | 0.0199 | 0.0209 | 0.0209 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | = 0.02 ug ml-1 | In vitro antibacterial activity against aerobically grown Pasteurella multocida (59A006) | ChEMBL. | 1311762 |
MIC (functional) | = 0.05 ug ml-1 | In vitro antibacterial activity against Aerobically grown Pasteurella haemolytica (59B018) | ChEMBL. | 1311762 |
MIC (functional) | = 0.1 ug ml-1 | In vitro antibacterial activity against anaerobically grown Actinobacillus pleuropneumoniae (54B004) | ChEMBL. | 1311762 |
MIC (functional) | = 0.2 ug ml-1 | In vitro antibacterial activity against aerobically grown Escherichia coli (51A538) | ChEMBL. | 1311762 |
MIC (functional) | = 0.2 ug ml-1 | In vitro antibacterial activity against aerobically grown Salmonella choleraesuis (58B015) | ChEMBL. | 1311762 |
MIC (functional) | = 0.2 ug ml-1 | In vitro antibacterial activity against aerobically grown Staphylococcus aureus (54B004) | ChEMBL. | 1311762 |
MIC (functional) | = 0.2 ug ml-1 | In vitro antibacterial activity against aerobically grown Escherichia coli (51A538) | ChEMBL. | 1311762 |
MIC (functional) | = 0.39 ug ml-1 | In vitro antibacterial activity against anaerobically grown Clostridium perfringens (10A009) | ChEMBL. | 1311762 |
MIC (functional) | > 1.56 ug ml-1 | In vitro antibacterial activity against aerobically grown Bordetella bronchiseptica (73A009) | ChEMBL. | 1311762 |
MIC (functional) | = 1.56 ug ml-1 | E. coli DNA cleavage endpoint value which is the minimum amount required (in micro g/mL) to induce detectable cleavage of supercoiled pBR322 substrate to linear form (gyrase) | ChEMBL. | 1311762 |
MIC (functional) | = 1.56 ug ml-1 | E. coli DNA cleavage endpoint value which is the minimum amount required (in micro g/mL) to induce detectable cleavage of supercoiled pBR322 substrate to linear form (gyrase) | ChEMBL. | 1311762 |
MIC (functional) | > 3.13 ug ml-1 | In vitro antibacterial activity against anaerobically grown Actinomyces pyogenes (14D002) | ChEMBL. | 1311762 |
MIC (functional) | = 3.13 ug ml-1 | In vitro antibacterial activity against anaerobically grown Bacteroides vulgatus (78D029) | ChEMBL. | 1311762 |
MIC (functional) | = 3.13 ug ml-1 | In vitro evaluation for antibacterial activity against anaerobically grown Treponema hyodysenteriae (94A007) | ChEMBL. | 1311762 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.